Monoclonal antibody 8H9 I-124 - Y-mAbs TherapeuticsAlternative Names: 124I-8H9; 124I-8H9 (B7-H3)
Latest Information Update: 05 Dec 2016
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action CD antigen modulators; Immunostimulants; Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Glioma